# "Debridement PhagE AnTibiotics for PJI"

> **NCT07698002** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 10 (estimated)

## Conditions studied

- Periprosthetic Infection

## Interventions

- **BIOLOGICAL:** The investigational product specifically targeting P. aeruginosa (DP-QB-PSA-005) and that targeting S. aureus (DP-QB-STA-005), each formed of a mixture of 5 bacteriophages.

## Key facts

- **NCT ID:** NCT07698002
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-02
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698002, ""Debridement PhagE AnTibiotics for PJI"". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*